Approach to the evaluation of adverse antibiotic reactions in patients with cystic fibrosis

Daniel Petroni(Allergy Asthma Research Institute), Andrew G. Ayars(University of Washington), Lori Menalia(University of Washington Medical Center), Sarah H. Chung(University of Washington), Matthew C. Altman(CGIAR), Moira L. Aitken(University of Washington), Erin Ham(University of Washington)

Annals of Allergy Asthma & Immunology

September 9, 2016

10.1016/j.anai.2016.07.039

Cited by 14

Related Papers

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation

|New England Journal of Medicine|2010|802

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

|Thorax|2011|496

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy

|JAMA|2019|271

Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy

|JCI Insight|2019|188

A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals

|EClinicalMedicine|2019|132